Satellos Bioscience Inc. (MSCL) Gets FDA IND OK For FSHD; Up To $5M Funding

Satellos received FDA clearance of its IND for forazapadin in FSHD and secured up to $5M in non-dilutive milestone funding from FSHD Canada. A Phase 2 study is expected to start in Q4 2026.Material DetailsContext by AI AnalystThis marks an expansion of forazapadin from DMD into FSHD, adding a secon…